News
Lilly’s Olomorasib Receives Second USFDA Breakthrough Therapy Designation
Lilly is currently evaluating olomorasib in the Phase 1/2 LOXO-RAS-20001 trial involving patients with KRAS G12C-mutant non-small cell lung cancer (NSCLC) and other advanced solid tumours.
imphoenix82
- August 3, 2026
- 0 Comments
- 65 Views
-
